Comparison of the effect of Yasmin and Cyproteron compound on metabolic syndrome in women with confirmed polycystic ovary syndrome

Trial Profile

Comparison of the effect of Yasmin and Cyproteron compound on metabolic syndrome in women with confirmed polycystic ovary syndrome

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/cyproterone (Primary)
  • Indications Metabolic syndrome; Polycystic ovary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
    • 12 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top